Literature DB >> 22871499

Prevalence and risk factors of non-alcoholic fatty liver disease in the elderly: results from the Rotterdam study.

Edith M Koehler1, Jeoffrey N L Schouten, Bettina E Hansen, Frank J A van Rooij, Albert Hofman, Bruno H Stricker, Harry L A Janssen.   

Abstract

BACKGROUND & AIMS: The prevalence of non-alcoholic fatty liver disease (NAFLD) appears to increase with age. However, limited data are available concerning the prevalence of NAFLD in the elderly. Our aim was to determine the prevalence and risk factors of NAFLD in an elderly population.
METHODS: This study was based on participants in the population-based Rotterdam Study. Each participant was interviewed and had a clinical examination at the research center, including a fasting blood collection, liver ultrasonography, and anthropometric assessment. Ordinal and logistic regression analysis was used to assess associations between covariables and (severity of) NAFLD.
RESULTS: Data from 2811 participants (mean age 76.4 ± 6.0 years) were analyzed. The prevalence of NAFLD was 35.1%. The prevalence of NAFLD decreased with advancing age (p<0.001). In logistic regression analysis, age (OR 0.97; 95% CI 0.95-0.99; p<0.001), total physical activity level (OR 0.98, 95% CI 0.96-0.99; p=0.005), pack years of smoking (OR 1.01, 95% CI 1.00-1.01; p=0.02), waist circumference >88 cm for women and > 102 cm for men (OR 4.89; CI 4.00-5.96; p<0.001), fasting glucose ≥ 100 mg/dl or drug treatment for elevated blood glucose (OR 2.11, 95% CI 1.72-2.59; p<0.001), blood pressure ≥ 130/85 mmHg or drug treatment for elevated blood pressure (OR 1.80, 95% CI 1.08-3.01; p=0.03), and triglycerides ≥ 150 mg/dl or treatment with serum lipid reducing agents (OR 1.56, 95% CI 1.28-1.91; p<0.001) were associated with NAFLD.
CONCLUSIONS: NAFLD is common in the elderly, although the prevalence decreases with advancing age. Further studies are warranted exploring potential factors contributing to this apparent positive selection effect in the elderly.
Copyright © 2012 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22871499     DOI: 10.1016/j.jhep.2012.07.028

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  65 in total

1.  The Rotterdam Study: 2016 objectives and design update.

Authors:  Albert Hofman; Guy G O Brusselle; Sarwa Darwish Murad; Cornelia M van Duijn; Oscar H Franco; André Goedegebure; M Arfan Ikram; Caroline C W Klaver; Tamar E C Nijsten; Robin P Peeters; Bruno H Ch Stricker; Henning W Tiemeier; André G Uitterlinden; Meike W Vernooij
Journal:  Eur J Epidemiol       Date:  2015-09-19       Impact factor: 8.082

2.  Association between non-invasive liver fibrosis scores and occurrence of health adverse outcomes in older people.

Authors:  Antonio De Vincentis; Luisa Costanzo; Umberto Vespasiani-Gentilucci; Antonio Picardi; Stefania Bandinelli; Luigi Ferrucci; Raffaele Antonelli Incalzi; Claudio Pedone
Journal:  Dig Liver Dis       Date:  2019-02-03       Impact factor: 4.088

3.  USF-1 genetic polymorphisms confer a high risk of nonalcoholic fatty liver disease in Chinese population.

Authors:  Ying Wang; Bai-Fang Wang; Jing Tong; Bing Chang; Bing-Yuan Wang
Journal:  Int J Clin Exp Med       Date:  2015-02-15

Review 4.  Central obesity and nonalcoholic fatty liver disease risk after adjusting for body mass index.

Authors:  Qing Pang; Jing-Yao Zhang; Si-Dong Song; Kai Qu; Xin-Sen Xu; Su-Shun Liu; Chang Liu
Journal:  World J Gastroenterol       Date:  2015-02-07       Impact factor: 5.742

Review 5.  Aging and adipose tissue: potential interventions for diabetes and regenerative medicine.

Authors:  Allyson K Palmer; James L Kirkland
Journal:  Exp Gerontol       Date:  2016-02-26       Impact factor: 4.032

Review 6.  Aging and liver disease.

Authors:  In Hee Kim; Tatiana Kisseleva; David A Brenner
Journal:  Curr Opin Gastroenterol       Date:  2015-05       Impact factor: 3.287

7.  The Rotterdam Study: 2018 update on objectives, design and main results.

Authors:  M Arfan Ikram; Guy G O Brusselle; Sarwa Darwish Murad; Cornelia M van Duijn; Oscar H Franco; André Goedegebure; Caroline C W Klaver; Tamar E C Nijsten; Robin P Peeters; Bruno H Stricker; Henning Tiemeier; André G Uitterlinden; Meike W Vernooij; Albert Hofman
Journal:  Eur J Epidemiol       Date:  2017-10-24       Impact factor: 8.082

8.  Aging increases the susceptibility of hepatic inflammation, liver fibrosis and aging in response to high-fat diet in mice.

Authors:  In Hee Kim; Jun Xu; Xiao Liu; Yukinori Koyama; Hsiao-Yen Ma; Karin Diggle; Young-Hyun You; Jan M Schilling; Dilip Jeste; Kumar Sharma; David A Brenner; Tatiana Kisseleva
Journal:  Age (Dordr)       Date:  2016-08-30

Review 9.  Mitochondria and Reactive Oxygen Species in Aging and Age-Related Diseases.

Authors:  Carlotta Giorgi; Saverio Marchi; Ines C M Simoes; Ziyu Ren; Giampaolo Morciano; Mariasole Perrone; Paulina Patalas-Krawczyk; Sabine Borchard; Paulina Jędrak; Karolina Pierzynowska; Jędrzej Szymański; David Q Wang; Piero Portincasa; Grzegorz Węgrzyn; Hans Zischka; Pawel Dobrzyn; Massimo Bonora; Jerzy Duszynski; Alessandro Rimessi; Agnieszka Karkucinska-Wieckowska; Agnieszka Dobrzyn; Gyorgy Szabadkai; Barbara Zavan; Paulo J Oliveira; Vilma A Sardao; Paolo Pinton; Mariusz R Wieckowski
Journal:  Int Rev Cell Mol Biol       Date:  2018-06-22       Impact factor: 6.813

Review 10.  Role of liver biopsy in nonalcoholic fatty liver disease.

Authors:  I L Ke Nalbantoglu; Elizabeth M Brunt
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.